Pemetrexed
Photos »
/ 
Related News »
LUX-Lung 3, which compares the investigational oral, once-daily therapy, afatinib, to pemetrexed/cisplatin, is the largest Phase III trial to date in first-line EGFR mutation-positive, advanced, metastatic NSCLC patients, and the first to use ...
May 16, 2012 at 23:38 | Source: Marketwatch
from June 1 - 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. Lilly presented ...
May 14, 2012 at 12:56 | Source: CNBC
from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA® (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.
May 27, 2012 at 23:11 | Source: Yahoo Finance
from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA® (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.
May 15, 2012 at 02:25 | Source: News-Medical.Net
LUX-Lung 3, which compares the investigational oral, once-daily therapy, afatinib, to pemetrexed/cisplatin, is the largest Phase III trial to date in first-line EGFR mutation-positive, advanced, metastatic NSCLC patients, and the first to use ...
May 17, 2012 at 04:17 | Source: News-Medical.Net
These included Novartis' everolimus and aliskiren, and Eli Lilly's pemetrexed. In the cases of everolimus and pemetrexed, the opinion of independent experts was not sought by the CDSCO, which relied on the judgment of non-medical staff ...
May 9, 2012 at 17:48 | Source: msnbc.com
Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion ...
May 23, 2012 at 10:08 | Source: Medscape News
Other brands such as Alimta (pemetrexed) and Xeloda (capecitabine) have also crossed the billion dollar mark in sales. However, these drugs are set to lose their patent protection in coming years, opening the market up to entry from generics. However ...
May 18, 2012 at 08:48 | Source: CNBC
If it’s adenocarcinoma AKT positive, we use crizotinib. If it is adenocarcinoma negative for both EGFR and AKT, we use a combination of cisplatin and pemetrexed. To complete the list, we should add small cell lung cancer (increasingly rare) where we use ...
May 20, 2012 at 00:39 | Source: star.com.my